by The global colorectal cancer diagnostics market size reached USD 14.25 billion in 2023 and is predicted to rise around USD 33.48 billion by 2033, growing at a CAGR of 8.92% from 2024 to 2033.
Key Points
- The North America colorectal cancer diagnostics market size accounted for USD 5.70 billion in 2023 and is expected to attain around USD 13.56 billion by 2033.
- North America dominated the market with the largest revenue share of 40% in 2023.
- Asia- Pacific is observed to be the fastest growing market during the forecast period.
- By test type, the imaging test segment has contributed more than 49% of market share of 2023.
- By test type, the blood test segment is observed to be the fastest growing market during the forecast period.
- By end-use, the hospitals segment has held the major revenue share of 42% in 2023.
- By end-use, the diagnostic imaging centers segment is observed to be the fastest growing in the market during the forecast period.
The colorectal cancer diagnostics market encompasses a wide array of tools and techniques aimed at early detection, diagnosis, and monitoring of colorectal cancer, which is one of the most prevalent and deadly forms of cancer worldwide. This market includes various screening tests, imaging modalities, and molecular diagnostics used by healthcare professionals to identify colorectal cancer at different stages, thereby enabling timely intervention and treatment.
Get a Sample: https://www.precedenceresearch.com/sample/4308
Growth Factors
Several factors drive the growth of the colorectal cancer diagnostics market. These include the rising incidence and prevalence of colorectal cancer globally, particularly among aging populations. Additionally, increased awareness about the importance of early detection and screening programs, advancements in diagnostic technologies such as molecular biomarkers and imaging techniques, and government initiatives to promote cancer screening are all contributing to market expansion.
Region Insights:
The colorectal cancer diagnostics market exhibits variations in demand and adoption across different regions. Developed regions such as North America and Europe lead in terms of market share due to the presence of well-established healthcare infrastructure, higher healthcare expenditure, and proactive screening initiatives. However, emerging economies in Asia-Pacific and Latin America are witnessing rapid growth driven by improving healthcare infrastructure, rising disposable income, and increasing awareness about cancer screening programs.
Colorectal Cancer Diagnostics Market Scope
| Report Coverage | Details |
| Growth Rate from 2024 to 2033 | CAGR of 8.92% |
| Colorectal Cancer Diagnostics Market Size in 2023 | USD 14.25 Billion |
| Colorectal Cancer Diagnostics Market Size in 2024 | USD 15.52 Billion |
| Colorectal Cancer Diagnostics Market Size by 2033 | USD 33.48 Billion |
| Largest Market | North America |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | By Test Type and By End-use |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Colorectal Cancer Diagnostics Market Dynamics
Drivers
Key drivers influencing the colorectal cancer diagnostics market include the growing geriatric population, which is more prone to developing colorectal cancer, and lifestyle factors such as sedentary lifestyles, unhealthy dietary habits, and obesity. Moreover, advancements in diagnostic technologies such as next-generation sequencing (NGS), liquid biopsy, and artificial intelligence (AI) are enhancing the accuracy and efficiency of colorectal cancer detection, thereby driving market growth.
Opportunities
There are several opportunities for market players in the colorectal cancer diagnostics segment. These include the development of non-invasive or minimally invasive diagnostic methods, expansion into emerging markets with high unmet medical needs, and strategic collaborations with research institutions and healthcare providers to advance diagnostic technologies and improve patient outcomes. Moreover, the integration of AI and machine learning algorithms into diagnostic workflows presents opportunities for improving efficiency and accuracy in colorectal cancer diagnosis.
Challenges
Despite the promising growth prospects, the colorectal cancer diagnostics market faces several challenges. These include the high cost associated with advanced diagnostic technologies, particularly in developing regions with limited healthcare budgets. Additionally, issues related to patient compliance and participation in screening programs, as well as the lack of awareness about colorectal cancer screening among certain population segments, pose challenges to market growth. Regulatory hurdles and reimbursement limitations in some regions also present obstacles to market expansion.
Read Also: Battery Power Tools Market Size to Rake USD 49.70 Bn by 2033
Colorectal Cancer Diagnostics Market Recent Developments
- In January 2024, A novel minimal residual disease (MRD) assay called Mx has been released by the technology company Tempus. It is intended for use in research on colorectal cancer (CRC). The xM assay is a plasma-based, tumor-naïve test that finds circulating tumour DNA (ctDNA) in blood samples from individuals who have had surgery for early-stage colorectal cancer. The xM assay, which is only now accessible for research purposes, is a liquid biopsy method of evaluating MRD that does not require baseline tumor tissue. Using methylation and genetic variation classifiers yields a binary MRD result.
- In November 2023, Leading precision oncology business Guardant Health, Inc. said it has introduced ShieldTM, a blood-based colorectal cancer screening test, in association with Samsung Medical Center in South Korea.
- In March 2023, With great pleasure, BGI Genomics announced the introduction of COLOTECTTM 1.0 in Slovakia, working with local partner Zentya. Zentya is a Slovak provider of healthcare solutions committed to giving patients access to cutting-edge genetic screening technology to help diagnose and expedite the treatment of hereditary illnesses.
Colorectal Cancer Diagnostics Market Companies
- Abbott Laboratories
- BioMerieux SA
- Dickinson and Company
- GE Healthcare
- Qiagen N.V
- Thermo Fischer Scientific
- Hologic Inc
- Epigenomics AG
- F-Hoffmann-La Roche Ltd
- Siemens Healthineers
- Sysmex Corporation
Segments Covered in the Report
By Test Type
- Blood Test
- Stool Test
- Fecal Occult Blood Test (FOBT)
- Fecal Biomarker Test
- CRC DNA Screening Test
- Imaging Test
- Computed Tomography (CT) scan
- Ultrasound
- Magnetic Resonance Imaging (PET) scan
- Positron Emission Tomography (PET) scan
- Colonoscopy
- Other Imaging Tests
- Biopsy
- Other Test Types
By End-use
- Hospitals
- Diagnostic Imaging Centers
- Cancer Research Centers
- Others
By Geography
- North America
- Asia Pacific
- Europe
- Latin America
- Middle East & Africa
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
Blog: https://www.expresswebwire.com/
